Results
1 -
10 of
13Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man, European Journal of Clinical Pharmacology Selective Amine Oxidase Inhibitors: Basic to Clinical Studies and Back, Clinical Pharmacology in Psychiatry On the reversibility of reversible MAO inhibitors, Naunyn-Schmiedeberg's Archives of Pharmacology Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone, Psychopharmacology Basic and Clinical Aspects of the Activity of the New Monoamine Oxidase Inhibitors, Psychopharmacology: Current Trends Reboxetine prevents the tranylcypromine-induced increase in tyramine levels in rat heart, Amine Oxidases: Function and Dysfunction The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222, Naunyn-Schmiedeberg's Archives of Pharmacology Estimation of the elimination half-life of the monoamine oxidase inhibitor cimoxatone in rat brain on the basis of ex vivo inhibition data, European Journal of Drug Metabolism and Pharmacokinetics Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS, Journal of Neural Transmission Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors, Psychopharmacology